SmartTRAK highlights what’s new in orthopedics and sports medicine, with a spotlight on Smith & Nephew (SNN). We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, research, financial data and competitor developments in the global life sciences industry.

In the market for Peripheral Nerve Stimulation (PNS), companies are developing new wireless or minimally invasive technologies with novel waveforms and form factors designed to treat a wide variety of applications and unmet clinical needs, including for the treatment of intractable migraines, chronic intractable postoperative pain, suprascapular neuralgia, low back pain, tibial/ankle pain, stroke rehab, overactive bladder and tibial nerve stimulation, to name a few.

MedTech Strategist reported that In May of this year, the Deloitte Center for Health Solutions conducted "an online survey of 50 clinical and service line leaders at US provider organizations on their deferred procedures". With the return of elective procedures being integral to a comeback for the MedTech industry, the results of that survey suggest that the path to resuming these procedures is becoming more complicated.

According to the Deloitte survey, "Respondents expect the return to pre-COVID-19 productivity volumes to take two to six months, with three months the typical estimate. When asked to list their top concerns about resuming deferred procedures, providers say a second coronavirus outbreak is their biggest worry (82%)". It appears that their biggest fear, a COVID-19 resurgence, may be coming to pass.

The following is just a small sampling of recent updates regarding the Life Sciences industry's COVID-related delayed procedures and what an impact a resurgence may have. These updates are compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

We are pleased to announce that Matt Golembeski has joined the team at SmartTRAK as Director of Sales. Matt has 15+ of sales and sales management experience in the medical device industry with a concentration in spine and spine-supportive technologies.

We are pleased to announce that Tim Patrick has joined the team at SmartTRAK as Senior Manager of Corporate Accounts. Tim has 5+ years experience in Medical Device Sales and Healthcare IT. Tim had prior roles at Zimmer Biomet and Abbott Laboratories.

Meet Tim Patrick:

What is your role with SmartTRAK? I’ve joined the commercial team as a Senior Manager of Corporate Accounts.

What do you like about SmartTRAK? It’s tough to keep this question to a paragraph, but I will do my best! The space, product and people are what really intrigues me about SmartTRAK. The Medtech/Software space is ever changing and as dynamic of a space that I’ve been involved with. The product is absolutely incredible. The type of data we provide at your fingertips is a must have. Lastly, I’ve come from large Fortune 500 companies who have claimed to be a tight knit team but nothing compares to what we currently have at SmartTRAK. From the other reps, analysts, and up to the CEO it truly is the best culture I have ever been a part of.

Facing the prevailing headwinds of the pandemic, the MedTech industry presses on with product innovation and plans for the future. SmartTRAK reports daily on the challenges still ahead, covering all aspects of the Orthopedic market: Extremities, OrthoBio, Spine, Computer Assisted Surgery, Total Joints, Trauma, Soft Tissue Fixation and EU Extremities and Trauma.

The following is just a small sampling of the Orthopedic updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry.

Although COVID-19 has disrupted the medical device market, with many elective procedures being postponed, SmartTRAK anticipates the Trauma market to recover in 2021 and beyond. We anticipate that US Trauma fracture fixation procedures will be only slighted impacted by COVID-19, resulting in nearly flat YoY growth from 2019 to 2020 and believe that 2021 procedures will return to normal. This will result in 2021 procedural growth rates being inflated at ~10% and 2022 experiencing normal growth trends as volumes begin to stabilize. 

Despite the unprecedented challenges of the ongoing pandemic, and the collateral economic hit taken due to the massive decline in elective procedures in Q220, MedTech companies continue to innovate and introduce new products to the global life sciences industry.

The following is just a small sampling of the new products updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, financial data and competitor developments in the global Life Sciences industry.

As the COVID-19 continues to affect every aspect of life, the MedTech industry perseveres in its attempt to adapt and continue moving forward. SAWC and the Wound Healing Society held the SAWC Spring 2020 as a virtual experience on July 24-26. In their words "At a time when so much else is canceled, the work to treat, manage, and prevent chronic wounds and improve patient care cannot stop. Hope must go on."

The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts, including many from SAWC 2020. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.